StockNews.com Begins Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research note published on Friday morning. The firm issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

Shares of BLPH opened at $0.04 on Friday. The firm’s 50-day simple moving average is $0.04 and its 200 day simple moving average is $0.05. The firm has a market cap of $428,050.00, a P/E ratio of -0.04 and a beta of 0.70. Bellerophon Therapeutics has a 52 week low of $0.03 and a 52 week high of $0.46.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.